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ABSTRACT 	  
Endophytes are bacterial and fungal microbes that live inside of plant tissue without 
causing disease.  Endophytes have applications in many industries including the pharmaceutical 
and food industries as producers of natural products.  This potential was demonstrated by 
investigating  the natural product production from a Bacillus amyloliquefaciens  endophyte of 
Platanus occidentalis using a combination of MALDI-IMS, LC-MS, MS-MS, and NMR 
methods, by purifying nicotianamine from soy flour, and by reviewing natural product inhibitors 
of the hepatitis C virus (HCV). 
 The secondary metabolite production of the endophytic B. amyloliquefaciens was 
investigated under a variety of fermentation conditions.  It was discovered that the endophyte 
produces rapamycin, a molecule previously reported only from Streptomyces hygroscopicus 
from Easter Island in the South Pacific. Other known natural products from the Bacillus genus 
were identified using LC-MS including the lipopeptide fengycins, surfactins, and iturins.  Iturin 
A3 was isolated and characterized from the endophyte, and found in the host P. occidentalis, as 
shown by LC-MS.  The presence of a possible rapamycin analogue was discovered which would 
be indicative of a biotransformation process. Challenge experiments were conducted using 
MALDI-IMS in an attempt to understand host regulation of secondary metabolites.  Iturin 
production increased as shown by MALDI-IMS. 
The impetus for studying endophytes like B. amyloliquefaciens for natural products was 
further exemplified by purifying a natural metal chelator, nicotianamine, from soy flour.  This is 
a possible candidate to replace ethylenediaminetetraacetic acid (EDTA), a synthetic metal 
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chelator used to prevent food spoilage.  Further studies on possible endophytic production of 
nicotianamine could be of great importance to many food companies.  The importance of  
studying endophytes was further shown by reviewing the number of novel and known natural 
products that have been reported with activity against the hepatitis C virus (HCV).  There are 
numerous examples in the literature of metabolites being reported as plant-derived which are 
later identified as ultimately being produced by endophytic organisms.  This review 
demonstrates the importance of studying new and known sources of HCV active metabolites for 
endophytic organisms. 	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CHAPTER ONE: INTRODUCTION 	  
Endophytes are bacterial and fungal microbes that live inside of plant tissue without causing 
disease.  Endophytes have applications in many industries including the pharmaceutical and food 
industries as producers of natural products.  This potential was demonstrated by investigating  
the natural product production from a Bacillus amyloliquefaciens  endophyte of Platanus 
occidentalis using a combination of MALDI-IMS, LC-MS, MS-MS, and NMR methods, by 
studying the production of nicotianamine from soy flour, and by reviewing natural product 
inhibitors of the hepatitis C virus (HCV). 
 The secondary metabolite production of the endophytic Bacillus amyloliquefaciens was 
investigated under a variety of fermentation conditions.  It was discovered that the B. 
amyloliquefaciens produces rapamycin, a molecule previously reported only from Streptomyces 
hygroscopicus from Easter Island in the South Pacific. Other known natural products from 
Bacillus sp. were identified using LC-MS including the antifungal lipopeptide fengycins, 
surfactins, and iturins.  Iturin A3 was isolated and characterized from the endophytic B. 
amyloliquefaciens, and found in  the host P. occidentalis, as shown by LC-MS.  The presence of 
a possible rapamycin analogue was discovered which would be indicative of a biotransformation 
process. Challenge experiments were conducted using MALDI-IMS in an attempt to understand 
host regulation of secondary metabolites.  Iturin production increased as shown by MALDI-IMS. 
The impetus for studying endophytes like B. amyloliquefaciens for natural products was 
further exemplified by purifying a natural metal chelator, nicotianamine, from soy flour.  This is 
a possible candidate to replace ethylenediaminetetraacetic acid (EDTA), which is a synthetic 
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metal chelator that is used to prevent food spoilage. Further studies on possible endophytic 
production of nicotianamine could be of great importance to many food companies.  The 
importance of endophytes was further demonstrated by reviewing natural product hepatitis C 
virus (HCV) inhibitors.  There are numerous examples in the literature of metabolites being 
reported as plant-derived which are later identified as ultimately being produced by endophytic 
organisms.  This review demonstrates the importance of studying new and known sources of 
HCV active metabolites for endophytic organisms.  
 Platanus occidentalis and Bacillus amyloliquefaciens  
Platanus occidentalis (American Sycamore) is an Eudicotyledon species of tree that has a 
native range that primarily exists east of the Great Plains region in the United States but also 
extends into parts of southern Ontario and the mountainous region of northeastern Mexico 
(Figure 1).1 Fully mature trees are characterized by exfoliating bark that leaves portions of inner 
bark exposed and leads to a patchwork appearance with different areas of grey, brown, white, 
and green.  Trees are deciduous and leaves are palmate-veined with three to five lobes per leaf 
and are among the largest trees in Eastern deciduous forests.  American Sycamore is a fast-
growing species often grown in plantations for pulp or dimensional lumber products.1 It has been 
used in the rehabilitation of saturated soils and strip-mined land and is an early colonizer of 
waterway disposal sites and degraded stream banks.  Ethnobotanic uses by Native Americans 
include the treatment of colds, respiratory ailments, as gastrointestinal and gynecological aids, 
and for uses in dermatological problems.1 Previously, one known and three novel glycosides 
were isolated from P. occidentalis leaf tissue that showed significant activity against MRSA 
(Figure 2).2 In order to more fully understand the pharmacological potential of this native tree, 
the secondary metabolite production of an endophyte that is involved in a mutualism with P. 
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occidentalis was studied. 
Mutualism is an association between two organisms that benefits both organisms.  These 
types of associations abound in nature and certain mutualistic relationships play important roles 
in plant health.  For example, mycorrhizal fungi form symbiotic relationships with plant roots 
whereby plants gain increased surface area for mineral and water absorption from the soil while 
the fungal symbionts derive nutrition from plant-produced carbohydrates.  Plants contributing in 
this symbiosis are more resistant to drought and disease.3-4 Plants benefit in a number of other 
ways through this association, many of which are still being researched.  It is currently estimated 
that 80% of plant species and 92% of plant families  
 
	  
Figure 1 Platanus occidentalis species with leaf inset 
 
have mycorrhizal associations with fungi.5 Another important mutualism exists between plants 
and nitrogen-fixing bacteria whereby bacteria dwelling inside the root nodules of certain plant 
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species fix nitrogen and make it available to the host plant and, after the host dies, to the soil.  
Yet another important mutualism exists between bacterial and/or fungal microbes and their plant 
hosts.  
Endophytes are bacteria and/or fungi that reside in living plant tissue without causing 
disease.  There are examples of bacterial and fungal species that can exist as both endophytes 
and pathogens depending on many factors including different stages of the microorganism’s life 
cycle or environmental conditions.  Thus, the nature of the host-microbe association must be 
taken into account when labeling a microorganism as an endophyte.6 Although estimates vary, it 
is currently accepted that there are over 300,000 higher plants on Earth, and each species that has 
been examined for endophytes  
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Figure 2 MRSA active glycosides isolated from P. occidentalis leaf tissue 
has contained them.  One of the best studied endophyte and plant host mutualisms occurs 
between fungal endophytes and various grasses. It has been shown in native grasses that the 
presence of fungal endophytes decreases herbivory.7  These fungal endophytes produce 
insecticidal alkaloids that have proven activity against both vertebrates and insect pests.8 The 
ecology of endophytes and how they contribute to plant health is an active and compelling area 
of research.  One of the recognized functions of endophytes is to provide natural products to the 
host plant that aid in protection and survival.  Many of these compounds have human uses in 
agriculture, industry, and in medicine as antibiotics, antimycotics, immunosuppressants, and as 
chemotherapeutic compounds.9 One of the endophytes that was isolated from P. occidentalis was 
identified by colony morphology, and later by 16S rRNA analysis, as  B. amyloliquefaciens. 
 
	  
Figure 3 Transmission electron microscopy image of Bacillus subtilis.  Endospore is shown.  
(Photo courtesy of NCI at Frederick: http://ncifrederick.cancer.gov/atp/cms/wp-
content/uploads/2010/11/bacteria_021.jpg)  
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Bacillus spp. are rod-shaped, motile, and aerobic.  They can produce endospores to 
survive unfavorable conditions and, until the advent of molecular phylogenetics, this was the 
defining characteristic that placed a bacterium within the genus.10 B. subtilis is used as a model 
organism for Gram-positive bacteria and is one of the most well known and studied Gram-
positive species (Figure 3).  The fact that B. subtilis and other Bacillus species can form such 
hardy spores, and that these spores are often dispersed by wind, has made characterizing the 
preferred environment of B. subtilis difficult.11 However, there is mounting evidence that the 
environments where B. subtilis can survive are extremely diverse.  These include soil, plant 
roots, and within the GI tract of animals.11 Soil dwelling B. subtilis species have been shown to 
be involved in plant growth promotion.12 The presence of B. subtilis spores in the GI tract of 
many animals including humans has been known for many years, and this was assumed to be due 
to the ingestion of food contaminated by spores.  However, there is  growing evidence that B. 
subtilis are  actually involved in a mutualistic relationship with the host animal species.13  
The full genome of B. subtilis was published in1997.14 The genome was reported to contain 
4,214,810 base pairs which correlated with 4,100 protein coding genes.  Interestingly, a number 
of these genes are devoted to the production of proteins involved in the utilization of plant-
derived molecules.14 
Some other commonly known Bacillus species are B. anthracis, B. thuringiensis, and B. 
cereus.  B. anthracis causes anthrax by producing the anthrax toxin that has been developed into 
a biological weapon by a number of countries.  B. thuringiensis produces pesticidal crystal 
proteins and is the most widely used biorational pesticide.15 Certain B. cereus strains are 
responsible for a number of food poisoning cases. 
 The genome of B. amyloliquefaciens FZB42 strain was comparatively analyzed in 
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2007.16 The particular B. amyloliquefaciens strain that was analyzed, B. amyloliquefaciens 
FZB42, has been reported as a rhizobacterium.  It was reported that more than 8.5% of the 
genome was devoted to synthesizing siderophores and antibiotics using non-ribosomal 
pathways.16 A number of genes that were previously identified as being involved in bacterium-
plant interactions were also identified.  These include genes involved in: the production of an 
exopolysaccharide that holds bacterial cells together; the production of surfactin for the 
colonization of plant surfaces; and the production of extra-cellular macromolecular 
depolymerases for growing on plant surfaces.16 A number of PKS and NRPS genes were also 
identified, although the putative synthetic secondary metabolites are unknown.16 
The secondary metabolite production of Bacillus spp. was reviewed comprehensively by 
Sansinenea and Ortiz in 2011.17  Bacillus spp. produce a diverse array of natural products 
including bacteriocins, lantibiotics, lipopeptides, and polyketides.17  Bacteriocins are peptides or 
proteins that can vary in structure and molecular weight and typically are active against bacteria 
that are closely related to the producer organism.  A  B. licheniformis strain which was isolated 
from buffalo rumen produces lichenin, a bacteriocin with a mass of approximately 1400 daltons 
and length of 12 amino acids.18 A bacteriocin peptide of 44 residues called coagulin, produced 
by B. coagulans, has proven antilisterial activity.19 Polyfermenticin SCD is another bacteriocin 
produced by B. polyfermenticus that has shown narrow spectrum activity against certain bacteria 
as well as yeasts and molds and has a mass of approximately 14.3 kilodaltons.20  
Lantibiotics are a group of polycyclic compounds that are formed by the posttranslational 
modification of serine and threonine residues.  These residues are dehydrated and then the thiol 
group of cysteine residues are added in intramolecular reactions to form lanthionine and 
methyllantionine bridges.21 B. subtilis produces many lantibiotics including subtilin, ericin, and 
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mersacidin, among others.22 Subtilin is by far the most widely studied of this group of secondary 
metabolites.  It is composed of 32 amino acids and has activity against mostly Gram-positive 
species as well as many pathogenic fungi.23 Another group of secondary metabolites that has 
been isolated from Bacillus species are the lipopeptides (Figure 4).17 Lipopeptides consist of a 
short fatty acid chain linked to a linear or cyclized peptide.24 Certain lipopeptides have exhibited 
antimicrobial, immunosuppressant, and cytotoxic activity.24-26 
 
 
	  
Figure 4 Representative examples of the famlies of lipopeptides produced by Bacillus spp.  (A) 
surfactins,  (B) iturins, and  (C) fengycins. 
The three groups of lipopeptides produced by Bacillus spp. are the surfactins, iturins, and 
fengycins.  These groups are defined by the number of amino acids within the cyclized peptide 
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moiety. Variants within groups are established by having different amino acid residues at 
different positions or differences in the lipid tail.24 Most of these molecules also have 
demonstrated surfactant properties and the most widely studied lipopeptides are the surfactin 
group.27 The surfactin group contains molecules with a heptapeptide moiety linked to a β- 
hydroxy fatty acid chain.24 Surfactin 5 has demonstrated biosurfacant properties, as well as 
antiviral and antimycoplasma activity.28 The iturins contain seven cyclized amino acids and a β- 
amino fatty acid.  They are differentiated by variations of amino acids at  different positions and 
also by variation in the branching or length of the β- amino fatty acid.29 Iturins have 
demonstrated activity against fungal plant pathogens including Podosphaera fusca,29 Rhizoctonia 
solani,30 and a number of iturin-producing Bacillus species are currently in use as bio-control 
agents for many other fungal pathogens.31  The fengycin group of lipopeptides contain 10 amino 
acids, eight of which form a lactone via a linkage between tyrosine and isoleucine. The β- 
hydroxy fatty acid is linked to the peptide moiety through an amide bond with the α-amino group 
of glutamic acid.24 Members of this group of lipopeptides have shown selective activity against 
filamentous fungi and certain agricultural pests.32 
Polyketides are another group of secondary metabolites that have been isolated from B. 
subtilis (Figure 5).  Difficidin and oxydifficidin are two macrocyclic polyene lactone phosphate 
esters that were first isolated and characterized in 1987 from B. subtilis.33 Difficidin has also 
been isolated from the plant-associated B. amyloliquefaciens and has proven activity against fire 
blight in orchard trees caused by Erwinia amylovora.34-35 Bacillaene is another polyketide that 
was reported from B. subtilis in 1995 and has also recently shown activity against E. 
amylovora.34  The production of bacillaene was discovered to be through an approximately 80 kb 
pksX gene cluster that encodes an uncommon polyketide/nonribosomal peptide synthase.36 
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Multiple copies of this synthase form a megacomplex with an expected mass of tens to hundreds 
of megadaltons to produce bacillaene, which contains two amide bonds and is not cyclized.36 
Macrolactins are a group of compounds which contain three separated diene components within 
a 24-membered lactone.  The first macrolactin was isolated from an unidentified deep sea 
bacterium.37 Macrolactin F was later isolated from an identified marine Bacillus sp. and 
	  
Figure 5 Representative examples of polyketides produced by Bacillus spp. (A) difficidin and 
oxydifficidin, (B) macrolactin F, and (C) bacillaene (stereochemistry unknown). 
macrolactin S has also been isolated from a Bacillus spp.  Macrolactin S showed unique activity 
against the Staph. aureus  FabG protein, and 7-O-malonylmacrolactin A, which showed activity 
against MRSA and vanomycin-resistant enterococci.38-39  
One of the most important polyketides from a drug discovery standpoint is rapamycin 
(Figure 6).  Rapamycin was first isolated from the actinomycete Streptomyces hygroscopicus, 
which was isolated from a soil sample collected on Easter Island in the southeastern Pacific 
Ocean in 1975.40-41 It was first reported as an antifungal product; subsequent studies 
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demonstrated rapamycin possessed significant activity against mammalian brain tumors42 and 
immune cells.43 Investigations into the mechanism of action of rapamycin led to the discovery of 
TOR 1-1 (Target of Rapamycin) and TOR2-1 genes in Saccharomyces cerevisiae.44 These genes 
are conserved in all eukaryotes, excepting metazoans which only contain one TOR gene, and are 
now known to code for serine/threonine protein kinases that are part of larger multiprotein 
complexes called TORC (TOR Complex) 1 and TORC 2.45-48  These 
	  
Figure 6 Rapamycin structure 
kinases are master regulators of eukaryotic cells, responsible for coordinating environmental 
signals with cell growth.45 
For many years, it was believed that plants were resistant to rapamycin.  However, it was 
shown that rapamycin inhibits root and leaf growth.49 Seedling and cellular assays were used to 
monitor TOR kinase activity by measuring S6 kinase (S6K) phosphorylation, and showed that, in 
plants, rapamycin inhibited the phosphorylation of Thr-449 and Thr-455 of S6K1 and S6K2, 
respectively. It had previously been shown that growth of Arabidopsis seedlings after 
germination strictly relies on glucose for growth.50 Using this newly developed assay, it was 
shown that glucose strongly activates TOR PK activity.  Subsequently, it was shown that the 
presence of rapamycin had a detrimental effect on seedling growth by interfering with glucose-
TOR signaling.  Seedlings grown in the presence of rapamycin had underdeveloped cotyledons, 
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leaves, petioles, and primary and lateral roots, leading to the conclusion that reports of plant 
resistance to rapamycin were false.49  A more recent paper further illustrated the importance of 
glucose-TOR signaling for plant development and growth.51 This study concentrated on the the 
photoautotrophic transition checkpoint, when a seedling transitions from acting as a heterotroph, 
relying on seed material, to a photoautotroph, synthesizing carbohydrates through 
photosynthesis.  It was discovered that glucose-TOR signaling has a direct relationship to root 
meristem stem/progenitor cell proliferation and overall plant growth through inter-organ 
coordination.51 The presence or absence of rapamycin was not linked to fluctuations in levels of 
auxins, or cytokines, or the the maintenance of the stem cell niche, but was instead specifically 
linked to changes in the cell cycle of the root meristem.  They discovered 1,318 up regulated and 
1,050 down regulated genes related to TOR-glucose signaling.  Interestingly, tor mutant plants 
did not undergo any of these transcriptome changes once again demonstrating the importance of 
TOR PK to plant development.51 
Rapamycin has recently proved to have some anti-aging properties in mice models.52 
Current data suggest that the prevention of cancer is responsible for life extension in mice as 
opposed to acting on aging itself. Rapamycin and rapamycin analogues are approved for the 
treatment of many different types of diseases.  Rapamycin is currently approved for use in 
kidney transplantation and has a mechanism of action that is unique from that of other 
immunosuppressants including tacrolimus and cyclosporin.53 These two agents act by inhibiting 
the transcription of calcineurin phosphatase, thus preventing the transcription of cytokines.  
Rapamycin exerts its effects through binding to mTOR and has the ability to synergize with 
other immunosuppressants.53 The rapamycin analog everolimus is approved for the treatment of 
subependymal giant cell astrocytoma (SEGA), advanced hormone receptor-positive, HER2-
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negative breast cancer, progressive neuroendocrine tumors of pancreatic origin, and advanced 
renal cell carcinoma.54 Temsirolimus is another derivative which was developed to decrease 
immunosuppressive properties and increase solubility and is approved for advanced renal cell 
carcinoma.55  
Imaging mass spectrometry (IMS) is a technology that is currently finding widespread 
use in drug discovery for the study of biomarkers56 and more recently the metabolism and tissue 
distribution of therapeutic agents.57 IMS has also emerged in the relatively recent past as a new 
tool in natural products research.  The use of IMS involves three basic steps, which can vary 
considerably depending on which ionization technique is involved.  For the work presented here, 
all IMS data were acquired using MALDI-IMS. In MALDI-IMS, the workflow can be divided 
into four steps: sample preparation, matrix application, measurement, and data analysis.58 A 
variety of techniques including MALDI-IMS, NMR, and LC-MS can be used to study endophyte 
produced metabolites. 
Nicotianamine 
Nicotianamine (NA) is found in all higher plants where it functions as a metal chelating 
compound in plant tissues, binding metal ions so they can be transferred throughout the plant.59  
	  
Figure 7 Nicotianamine structure 
 
Other possible roles include protecting plants from oxidative stress.60 Recent studies have shown 
that NA possesses antihypertensive effects, which are related to its ability to inhibit the 
angiotensin I-converting enzyme (ACE) in the renin-angiotensin system.61 Pharmacological ACE 
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inhibitors are widely used for the control of high blood pressure, as well as in the treatment of 
diabetic neuropathy and hypertensive related congestive heart failure.  The ACE enzyme must 
bind zinc in each active site for catalytic activity, leading to speculation that NA inhibited ACE 
activity via zinc chelation.  However, recent studies have shown that NA shows preferential 
inhibition towards ACE.  In one study, NA had a similar inhibition rate as the known metal 
chelator EDTA for the zinc-containing enzyme carboxypeptidase A.61 However, NA had a 15 
times higher inhibition rate for ACE than EDTA.61 NA has also shown great  
Table 1 Reported Enriched Sources of Nicotianamine Species	   Reported	  Yield	  of	  NA	  (μmol/g	  fr.	  Wt)	  
Datura	  metel	  	   0.12	  	  
Lycium	  chinense	   0.69	  	  
Solanum	  melongena	   0.05	  	  
Lycopersicon	  esculentum	  (tomato)	   0.05	  	  
Nicotiana	  tabacum	  B.	  Y.	  (tobacco)	   0.05	  	  
N.	  glutinosa	  (tobacco)	  
N.	  rustica	  (tobacco)	  
	   N.	  arentsii	  (tobacco)	   	  
N.	  alata	  (tobacco)	  
N.	  debneyi	  (tobacco)	  
0.07	  0.19	  0.12	  0.03	  0.13	  	  
Zea	  mays	   0.02	  	  
Rohdea	  japonica	   trace	  
Fagus	  silvatica	  (beechnuts)	  	   Not	  reported	  Soybeans	  	   0.3	  %	  aqueous	  extract	  of	  soybeans	  
 
 
promise as a replacement for EDTA as a food additive to prevent spoilage.62 Certain plant 
species have greater levels of nicotianamine in their tissue (Table 1).63,64  
Metal ions can act as catalysts for oxidative reactions that can cause spoilage in food 
products.  EDTA is a synthetic chelator that is presently added to many food products to 
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sequester metal ions and prevent oxidative reactions.  Utilizing NA as a natural metal chelator 
could allow companies to label food products as “all-natural” or organic and the market for these 
food products is continuing to increase.65 
Although all higher plants contain NA, two groups of plants, graminaceous and non-
graminaceous, can be differentiated based on NA use.  Graminaceous plants use it as a precursor 
in the biosynthetic production of the mugineic acid family of phytosiderophores, while non-
graminaceous plants do not utilize this pathway.  Graminaceous plants that thrive in iron 
deficient conditions show a higher degree of plasticity in regards to the NA synthase gene.66  
Another important distinction between plants with regards to NA production relates to plants 
involved in metal hyperaccumulation.  Thlaspi caerulescens can thrive in soil with 
concentrations of nickel that would be toxic to other plants, and more NA is produced and 
resistance to high nickel soil concentrations is conferred when the NA synthase gene from T. 
caerulescens is spliced into Arabidopsis thaliana.67  All of these considerations can be taken into 
account when deciding on source material for NA extraction.  Iron deficient conditions would 
only need to be utilized if the plant species is both graminaceous and adaptive to iron deficient 
conditions.  Soybeans and soy flour are readily available products which could be used to 
generate high yields of nicotianamine to replace EDTA in food products. 
The Hepatitis C Virus 
The hepatitis C virus (HCV) is responsible for chronic hepatitis C which can lead to 
cirrhosis of the liver and liver cancer and affects between 130-170 million people in the world 
today.68 More than 350,000 people die from chronic hepatitis C annually and an estimated 3-4 
million people are infected with HCV each year.68 About 25% of people in the United States 
who are infected with the human immunodeficiency virus (HIV) are also infected with HCV.68  
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Co-infection with HIV increases the risk of developing liver disease more than three fold.69 
There have been numerous studies showing that while HCV is primarily hepatotropic, it can also 
replicate in immune cells.70 
Serological tests were devised in the 1970s to detect both hepatitis A and B, leading to 
the discovery that an unknown, unidentified virus was responsible for many cases of viral 
hepatitis.71 In 1989, an immunoscreening approach which utilized a cDNA library created from 
clones of nucleic acids from HCV infected chimpanzees led to the identification of the hepatitis 
C virus.72 In 1991, the first detailed study of the genome reported a 9379-long nucleotide 
sequence with a large open reading frame (ORF) that was predicted to encode a large polyprotein 
containing 3011 amino acids.72 HCV was classified as a member of a new genus in the 
Flavivirus family; this family contains two other genera that encode a large polyprotein 
subsequently cleaved at multiple sites.73 There has been a persistent problem in culturing HCV in 
vitro, prompting researchers to rely heavily on cDNA technology to study HCV.  In 1993, a 
heterologous system using vaccinia viruses was used to elucidate the polyprotein cleavage 
products.73 In 1997, it was formally proved that HCV is the sole causative agent of hepatitis C by 
infecting chimpanzees with HCV cDNA.74 
A constant barrier to HCV drug development has been the absence of successful 
culturing methods for detailed studies of the life cycle.  There have been multiple techniques 
developed and refined over recent years to overcome this obstacle.  One technique involves 
psuedotyping viral particles (HCVpp) with the E1 and E2 envelope glycoproteins to study host 
cell entry.  Early reports using this technique utilized modified proteins which were poorly 
infective, however HCVpp were later reported which harbored unmodified glycoproteins and 
were highly infective.75 The complete culturing of HCV (HCVcc) by transfecting hepatoma-
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derived cell lines has also recently been achieved and refined, allowing for detailed studies of the 
HCV life cycle.76 These new techniques have allowed for a number of directly acting antiviral 
(DAA) agents to be developed which target specific proteins in the life cycle.  Natural products 
screening programs can use these targets to screen for novel inhibitors of HCV.
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CHAPTER TWO: 
SECONDARY METABOLITE PRODUCTION FROM A BACILLUS AMYLOLIQUEFACIENS 
ENDOPHYTE OF PLATANUS OCCIDENTALIS 
 
Endophytes are microbes that inhabit plant tissue without causing disease.  One of the 
functions of endophytes as part of a symbiotic mutualism with plants involves participating in 
defense mechanisms whereby the microbe produces antibiotics, antifungals, and growth 
promoting/inhibiting agents.  Here, we show that a Bacillus amloliquefaciens endophyte 
produces rapamycin for its plant host Platanus occidentalis and this molecule is then possibly 
biotransformed to yield a putative rapamycin analog.  MALDI-IMS of the endophyte  colonies 
and extraction and purification of liquid endophyte cultures showed rapamycin production by  B. 
amyloliquefaciens.  Extraction of host tissue produced the putative rapamycin analogue. Iturin A3 
production was indicated by LC-MS from healthy stem tissue of the host plant and from liquid 
fermentation of the endophyte. Thus, the endophyte and Platanus occidentalis host are involved 
in a mutualism in which the endophyte produces rapamycin which is possibly modified by the 
host plant and also produces iturin A3 which could be isolated from the host plant. This is the 
first report of rapamycin production from a new source since its original discovery from an 
Easter Island soil Streptomyces hygroscopicus in 1975 and reveals a significant ecological role 
for this highly important natural product.40-41 The data presented here illustrates a significant 
potential for discovery via silent gene expression.  This is also the first report of a mutualistic 
relationship between B. amyloliquefaciens and P. occidentalis, a potential biomass crop for the 
southeastern United States.
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Endophytes are microbial species which live inside of plant tissue without causing 
disease and all plant life is thought to harbor some species of endophytes. Endophytes have the 
ability to contribute to plant health in a multitude of ways.77-78 One function of endophytes is the 
participation in a mutualism whereby endophytic microbes produce antimicrobial and antiviral 
secondary metabolites that benefit the host plant as defense mechanisms while consuming plant 
produced carbohydrates.79  Novel and known compounds originally isolated from plant sources, 
with antimicrobial, immunosuppressant, and anticancer activity have been isolated from 
endophytes.80 Here, we show that a B. amyloliquefaciens from a common plant species produces 
rapamycin. The genome sequenced using Illumina software and assembled using Geneious 
software  by mapping assembly using B. subtilis reference sequence NC_000964.3.81-82  This has 
been a reference genome for more than 10 years and current annotations suggest B. subtilis is an 
epiphyte.81 Interestingly, low sensitivity and fast speed settings on Geneious genome assembly 
software gave much different results and showed the Bacillus endophyte to be much more 
closely related to B. subtilis then when settings were changed to higher sensitivity settings 
(Table 2).  The endophyte was fermented under a number of different conditions and only one 
certain group of culture ingredients supported the detection of rapamycin production. This was 
CS20 medium, a medium originally developed for the culturing of fastidious organisms.83 
MD5FL which had been used for rapamycin production by S. hygroscopicus did not support 
production,84 nor did the traditional Bacillus Landy’s medium, or CHARD2, a medium that was 
developed to mimic the conditions of xylem plant tissue.85  Iturin A3 could be shown from both 
endophyte cultures and P. occidentalis extracted stem tissue.  However, rapamycin could not be 
detected in plant host tissue.  This led to our hypothesis that rapamycin was possibly being 
biotransformed to a currently unknown molecule by the plant host.	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Table 2 Bacillus genome assembly Bacterial	  species	   Sequence	  length	   High	  quality%	   Identical	  sites	  	   Ambiguities	  	   Sensitivity/speed	  
Bacillus	  
subtilis	  	  
4,215,606	   -­‐	   -­‐	   -­‐	   -­‐	  
Bacillus	  endophyte	  	   4,214,756	   66.5%	   25.2%	   1,411,866	   low/high	  
Bacillus	  endophyte	   3,315,554	   98.9%	   15.3%	   51,780	   high/low	  	  
	  
Figure 8 Production of rapamycin and possible biotransfromation to a putative rapamycin 
analogue (A) P. occidentalis leaf tissue.  (B) MRSA-active glycosides from leaf tissue.2  (C) P. 
occidentalis stem tissue.  (D) Wounded stem tissue. (E) B. amyloliquefaciens emerging from 
stem tissue.  (F) Isolated B. amyloliquefaciens after excision from solid agar and transfer onto 
MALDI plate.  (G) MALDI-IMS of protonated rapamycin signal from B. amyloliquefaciens 
colony.  (H) Rapamycin structure.  (I) LC-MS of product of putative biotransformation product 
and rapamycin standard. 
Stem tissue material was collected from P. occidentalis species and, after surface 
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sterilization, the outer bark was removed to expose the vascular cambium layer and xylem tissue 
to solid malt-based agar (Figure 8 C-E).  Within 48 hours, bacterial and fungal growth could be 
detected emanating from host tissue (Figure 8 E).  The colony morphology of  bacterial growth 
showed characteristics of Bacillus sp. including an undulate margin and irregular shape (Figure 
8 F).  
Figure 9 Isolation of iturin A3 from B. amyloliquefaciens and P. occidentalis host.  (A) EIC from 
LC-MS monitoring the mass for the sodium adduct for iturn A3 at m/z 1079.6 [M+Na]+ from the 
crude ethanol extract from a B. amyloliquefaciens culture and methanol extract from P. 
occidentalis stem material.  (B) Stems of P. occidentalis. (C) B. amyloliquefaciens emerging 
from stem tissue.  (D) Isolated B. amyloliquefaciens after excision from solid agar and transfer 
onto MALDI plate. (E) MALDI-IMS of sodium adduct of iturin A3 [M+Na]+. 
  (F) HRMS and NMR of iturin A3.  (G) Structure of iturin A3.	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Figure 10 Isolation of rapamycin from B. amyloliquefaciens 
	  	  
	  
Figure 11 FTMS of rapamycin standard.  Ions are rationalized by successive losses of water and 
methanol in certain combinations.  Structures are coordinated with arrows by color. 
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Figure 12 FTMS of purified fraction from B. amyloliquefaciens.  Ions are rationalized by 
successive losses of water and methanol.  Structures are coordinated with arrows by color.  Ions 
that match rapamycin standard FTMS are highlighted. 
 
MADLI-IMS of bacteria over seven days showed production of rapamycin with the 
protonated signal being detected after day two (Figure 8 G). Interestingly, rapamycin production 
clearly stayed in the boundaries of the colony which strongly contrasted with the production of 
iturin which was excreted from the colony (Figures 8 G & 9 E).  Processed P. occidentalis  
xylem material showed a putative rapamycin analogue at m/z 935.7337 (Figure 8 I). 
Iturin A3 was shown from both endophytic B. amyloliquefaciens liquid cultures and 
directly from host P. occidentalis stem tissue (Figure 9).  The signal for the sodium adduct of 
iturin A3 was detected by LC-MS in an ethanol extract from a B. amyloliquefaciens culture as 
well as a methanol extract from processed stem material from P. occidentalis (Figure 9 A).  
Bacillus cultures were isolated directly from stem tissue and MALDI-IMS revealed the signal for 
the known Bacillus metabolite as iturin A3 (Figure 9 C-E).  Purification allowed for recording 
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NMR and HRMS data, which confirmed iturin A3 from endophyte cultures (Figure 9 F). 
Isolation of rapamycin from B. amyloliquefaciens followed the scheme shown in Figure 
10.  FTMS of liquid cultures of the B. amyloliquefaciens endophyte when compared to FTMS of 
a rapamycin standard verified that the detected signal by MALDI-IMS and LC-MS was 
rapamycin (Figures 11 & 12).  
 For example, it has been shown that with secondary metabolite production from 
filamentous fungi, it is important to have a media that is rich in amino acids, vitamins, and trace 
metals.86 The carbon source can also play an important role in the secondary metabolite 
production of both bacteria and fungi.87 In our studies, a media that had originally been 
developed for the culture of Xylella fastidiosa was used (Table 3).83 
 
Table 3 CS20 Media83 Distilled	  H2O	   1	  L	  Soy	  peptone	   2.0	  g	  Bacto	  tryptone	   2.0	  g	  (NH4)2HPO4	   0.85	  g	  Hemin	  Cl	  (0.1%)	   15.0	  mL	  KH2PO4	   	   1.0	  g	   	  MgSO4	  .7H2O	   0.4	  g	  L-­‐glutamine	   6.0	  g	  Dextrose	   1.0	  g	  Starch,	  potato	  soluble	   2.0	  g	  L-­‐histidine	   1.0	  g	  Phenol	  red	  (0.2%)	   5.0	  mL	  pH	   6.6-­‐6.7	  
 
As stated previously, the colony morphology of the sample was undulate with an 
irregular margin which conforms with the general description of the Bacillus genus  (Figure 
13).10  
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Figure 13 B. amyloliquefaciens morphology.	  	  The colony morphology is undulate with 
an irregular margin.  Image taken after colonies had been transferred to MALDI plate from solid 
agar. 
 
B. amyloliquefaciens colonies were grown in CS20 media83 and, in order to test for 
bioactivity, extracts were assayed for activity against pathogenic bacteria and fungi, malaria, and 
leishmaniasis using the NCNPR in-house screening protocol.  Although the first round of 
bioassay results were not encouraging, the project was continued due to the mistaken belief that 
we were dealing with a plant pathogen which would make the study of any secondary metabolite 
production, regardless of activity, important.  
 It was decided to continue this project, but start doing chromatography with extracts to 
get to higher levels of purity in hopes that more purified extracts would yield better activity.  
VLC with a number of different chromatography column materials including normal phase using 
silica gel (Silicycle Siliaflash® F60, particle size 40-63µm), size exclusion using Sephadex® 
LH-20, and reverse phase using C18 (SiliCycle C18, Carbon 17%, particle size 40-63 µm) were 
used. The first significant bioactivity results was retrieved from after a 1 L culturing of the 
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Bacillus amyloliquefaciens followed by reverse chromatography using the fractionation scheme 
in Figure 14. 
 
	  
Figure 14 Culturing and purification of endophytic Bacillus secondary metabolites. 
              Table 4 MRSA and Staph. aureus activity 
 
The IC50 values for extracts 4 (25% MeOH, 75% H2O), and 5 (100% MeOH) were 
significant (Table 4).  Fraction 5 was analyzed by LC-MS.  Strong signals were seen at m/z 
1492.2 along with other signals clustered around this signal ranging from m/z 1461.1 to 1506.2 
(Figure 15).  These signals correlate with the known Bacillus metabolites the fengycins.  
 IC50 Staph aureus IC 50 MRSA 
Fraction 1 (100% H2O) 0 0 
Fraction 2 (75% H2O, 25% MeOH) 0 0 
Fraction 3 (50% H2O, 50% MeOH) 0 0 
Fraction 4 (25% H2O,  75% MeOH) 0 13.35 
Fraction 5 (100% MeOH) 14.1 12.75 !
	   27	  
Fengycin lipopeptides are produced by non-ribosomal peptide synthetases (NRPSs) or through 
hybrid polyketide synthetases and non-ribosomal peptide synthetases (PKs/NRPSs) which can 
lead to multiple isoforms being produced naturally in B. subtilis as B. amyloliquefaciens 
extracts.88 They possess antibacterial activity.24 
	  
Figure 15 Fengycin ions.  Formulas are noted and match a number of different fengycin 
isoforms. 
 
All fengycins are decapeptides; different amino acids within the eight amino acid 
cyclized peptide moiety along with changes in length, branching, and saturation of the fatty acid 
tail are responsible for slight modifications in fengycin secondary metabolites.  Members of the 
fengycin A family have the following amino acid sequence: Glu-Orn-Tyr-Thr-Glu-Ala-Pro-Gln-
Tyr-Ile.  Fengycin B isoforms have a valine substituted for alanine (Figure 16).  Other isoforms 
exist and new ones continue to be discovered.89 Rapid methods using FTMS have been 
developed to discern which fengycin metabolites are being observed as there can be significant 
overlap in [M+H]+ ions from one family to another depending on amino acid substitutions and 
fatty acid chain composition.90 All ions that were found have previously been reported from 
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fengycin-producing Bacillus spp.91 Another cluster of ions was seen in fraction five between m/z 
1008.9 to m/z 1044.9 (Figure 17).  These signals correlate with the known Bacillus secondary 
metabolites the surfactins.17,91  These are heptapeptides with some heterogeneity at different 
positions in the peptide moiety.  All members are lactones and are linked to a fatty acid tail that 
can vary in length (Figure 18).   
The final known lipopeptide family of molecules that are produced by Bacillus spp. are 
the iturins.  The iturins contain seven cyclized amino acids moieties and a β-amino fatty acid.  
They are differentiated by variations of amino acids at different positions and also by variation in 
the branching or length of the β- amino fatty acid.29 A cluster of signals correlating with the 
iturin molecules was seen by LC-MS (Figure 19). As with other previously discussed Bacillus 
lipopeptides, there can be significant overlap between different isoforms and homologues when 
trying to decipher exactly which molecule is being observed and MS/MS methods are often used 
for this purpose.  
Fraction 5 was put through HPLC to further purify Bacillus metabolites (Figure 20). UV 
wavelengths of 215 nm and 254 nm were used to analyze the samples. Two sharp signals were 
seen at 215 nm (Figure 21).  These correlated with two iturin homologues (Figure 22).  HRMS 
and NMR showed these to be iturin A2 and iturin A3 (Figure 23).  As noted previously, it is 
important to use MS/MS methods for full identification of iturin peptides.  Therefore, only 
purified metabolites were assigned completely.  Numerous publications dealing with lipopeptide 
production have assigned these metabolites using MS/MS.  
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Figure 16 Fengycin isoforms (A) Fengycin A contains alanine in the indicated position.  (B) 
Fengycin B contains valine in the indicated position.  Many different members of both families 
are found based on differences in length and saturation in the fatty acid tail.  
	  
Figure 17 Surfactin ion signals.  Formulas are noted and match many different surfactin 
isoforms. 	  
	   30	  
	  
Figure 18 Surfactin homologues.  (A) differs from structure (B) by a methylene unit. 	     	  
	  
Figure 19 Iturin ions.   	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Figure 20 Iturin isolation scheme 
	  
Figure 21 Purification of iturin homologues 
	   32	  
 
	  
Figure 22 Iturin homologues.	  	  Structure (A) differs from structure (B) by a methylene unit.  
Structure (A) represents iturin A2.  Structure (B) represents iturin A3. 
 
 
	  
Figure 23 Purified iturin homologues.  (A) HRMS for iturin A3.  (B) NMR for iturin A3.  (C) 
HRMS for iturin A2.  (D) NMR for iturin A2. 
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Figure 24 EIC of bacterial extract and rapamycin standard.	  	  Bottom panel shows three signals 
found in bacterial extract including m/z 931.6 [M+NH4]+, m/z 936.6 [M+Na]+,  
and m/z 952.6 [M+K]+ adducts. 
A signal was observed in fraction 4 which correlated with the ammonium adduct of 
rapamycin at m/z 931.6.  It was decided to use a rapamycin standard (LC Laboratories Cat. No. 
R-5000) to confirm that the signal was a rapamycin ammonium adduct by comparing the 
retention time of the standard to the ion found in the c18 fraction (Figure 24). 
A series of MALDI-IMS experiments were performed on the Bacillus sp. to test for 
rapamycin production.  In order to perform these experiments, the first step was to design the 
sample preparation steps so that consistent results could be obtained.  This step was particularly 
important as sample preparation is the step that introduces the most variability and can lead to 
difficulty in reproducing results in MALDI-IMS.92 The first process that needed to be developed 
was to be able to excise colonies from solid agar plates and place them on a Bruker MTP 384 
steel plate, being careful to not let any air bubbles form between the excised colony and the steel 
plate.  After this technique had been developed, it was important to test different thicknesses of 
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agar for the colonies to grow on, as it has been proven that a thinner sample improves peak 
intensity as well as the signal to noise ratio.93 However, the agar could not be too thin as the 
excised colony after matrix application had to be dehydrated prior to data acquisition and a 
sample that was too thin would not permit a vacuum to be applied for drying.  After a period of 
trial and error, the following protocol was developed. 
Seven CS20 agar plates were poured with days 1-5 poured with 10 mL of agar and plates 
for days 6 and 7 poured with 15 mL of agar.  Five µL of Bacillus sp. containing glycerol stock 
was placed in the center of each of these plates and placed in an incubator at 36°C.  One plate 
was removed every 24 hours and colonies were excised from the agar plate and placed on a 
Bruker MTP 384 steel plate.  After a picture of the colony was taken for later overlay using 
imaging software, alpha-cyano-4-hydroxycinnamic acid matrix was shaken on top of the colony 
using a 20 µm sieve for even distribution of the matrix.  The steel plate was then placed in an 
incubator at 36 °C for four hours.  Afterwards, the plate was placed in a desiccator.  The 
desiccator was then placed under vacuum for 5 minutes and then sealed and the plate was left 
inside for an additional 25 minutes.  The plate was then removed and placed into a Bruker 
Autoflex II mass spectrometer equipped with the Compass 1.1 software suite (consisting of 
FlexImaging 3.0, FlexControl 2.4, and FlexAnalysis 2.4).  The samples were analyzed in linear 
positive mode with 200 µm intervals.  The spectra were collected in the m/z 700-1600 range at a 
200 Hz laser frequency.  After data acquisition, the data was analyzed using FlexImaging 
software.   
The data acquired and analyzed after repeating this procedure for a time course 
experiment of seven days are shown in Figure 25.  The top panel shows the bacterial colony 
after being placed on the steel plate before the matrix was applied (note that days 3 and 5 are 
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omitted as there was a problem with transferring a colony from agar to plate).  The horizontal 
panel below this shows an ion at m/z 914.6 which correlates with the [M+H]+ ion of rapamycin 
which has a monoisotopic mass of  m/z 913.555. The third panel from the top shows the 
dehydration product for rapamycin at  m/z 895.7.  Finally, the lower panel shows the potassium 
adduct at m/z 952.3.   
	  
Figure 25 MADLI-IMS of Bacillus endophyte.	  	  Top panel shows bacterial colonies prior to 
matrix application.  2nd panel from top shows production of putative rapamycin signal at m/z 
914.6  [M+H]+.  3rd panel shows dehydration product at m/z 895.7 [M-H20]+. 4th panel shows 
potassium adduct at m/z 952.3 [M+K]+. 
 
In order to confirm the mass signal was rapamycin, an attempt was made to culture enough 
bacterial material to generate an NMR spectrum that could be overlaid with a rapamycin 
standard NMR spectrum.  Figures 26 and 27 show the fermentation protocols that were followed 
with the highlighted fraction containing the putative rapamycin signal.  In order to further test if 
retention times for rapamycin would match the putative rapamycin metabolite, standard 
rapamycin was injected on a Phenomenex Luna 5u C18(2) 250 x 21.20 RP column.  A gradient 
was run that started 15 minutes after injection and ran over an hour from 95% H2O/ 5% MeCN to 
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100% MeCN. The retention time was approximately 78 minutes. Note that UV data are not 
shown as rapamycin contains a weak chromophore consisting of a conjugated triene system with 
a peak intensity at 278 nm and the bacterial extract did not show UV absorption.  Instead, the 
putative bacterial rapamycin molecule was isolated by using the retention time that had been 
shown from the standard rapamycin.  Approximately 20 mgs of the fraction containing 
rapamycin signal were injected following the same parameters that had been used for the 
standard.  
 
Figure 26 Isolation scheme for rapamycin 
	   37	  
 
Figure 27 Isolation scheme for rapamycin 
The fraction that was collected at 78 minutes could not be analyzed by NMR 
spectroscopy due to a low amount of material, however LC-MS confirmed that the putative 
rapamycin molecule from the Bacillus sample eluted at the same time as rapamycin. (Figure 28).   
	  
Figure 28 HRMS of rapamycin from Bacillus sp. 
	   38	  
	  
Figure 29 HRMS of rapamycin standard 
 
 
 Note that rapamycin standard has higher ppm value than Bacillus product.  Both 
of these values were within the accepted range for error values with the rapamycin formula of 
C51 H79 N O13.  These values were calculated by subtracting the observed mass from the 
calculated mass, dividing this number by the calculated mass, and then multiplying by 106.  For 
the Bacillus product this equation [(936.5449-936.5433)/936.5449] * 106.  For the rapamycin 
standard this was [(936.5449-936.5376)/936.5449] * 106. 
These two molecules can be noted as identical based on these masses.  However, it was 
important to gather NMR data to attempt to overlay the two spectra as a number of molecules 
can have identical monoisotopic masses.  This data was gathered after multiple HPLC 
purifications were ran using the same procedures that have been previously outline for iturin 
purification.  
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Figure 30 Rapamycin and B. amyloliquefaciens fraction 1H-NMR overlay experiment.  Green 
chemical shifts represent rapamycin standard (CDCl3). Red chemical shifts represent purified 
metabolite from B. amyloliquefaciens (CDCl3). 
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Figure 31 Rapamycin and B. amyloliquefaciens fraction 1H-NMR overlay experiment.  Green 
chemical shifts represent rapamycin standard (CDCl3). Red chemical shifts represent purified 
metabolite from B. amyloliquefaciens (CDCl3).  Range is 2.4 ppm – 0.4 ppm. 
	  
Figure 32 Rapamycin and B. amyloliquefaciens fraction 1H-NMR overlay experiment.  Green 
chemical shifts represent rapamycin standard (CDCl3). Red chemical shifts represent purified 
metabolite from B. amyloliquefaciens (CDCl3) Range is 5.0 ppm – 2.5 ppm. 
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Figure 33 Rapamycin and B. amyloliquefaciens fraction 1H-NMR overlay experiment.  Green 
chemical shifts represent rapamycin standard (CDCl3). Red chemical shifts represent purified 
metabolite from B. amyloliquefaciens (CDCl3).  Range is 6.4 ppm - 4.9 ppm. 	  
HRMS is shown for the rapamycin standard to compare to the isolated rapamycin signal 
(Figure 29). After multiple purifications using HPLC, enough material was purified to obtain 
some NMR spectroscopic data.  An overlay of rapamycin standard (green) and rapamycin from 
Bacillus sp. (red) show the same chemical shifts for many signals from both fractions (Figure 
30).  Expansions focusing on chemical shifts from 0.4 ppm to 2.4 ppm (Figure 31), 2.4 to 5 ppm 
(Figure 32), and 4.9 to 6.4 ppm (Figure 33) clearly show signals that are overlain between 
rapamycin and the B. amyloliquefaciens product.Another experiment was done to further 
understand the relationship between the endophyte and the host P. occidentalis.  P. occidentalis  
tissue was extracted and analyzed by LC-MS in order to test whether or not metabolites that had 
been located in bacterial extracts could also be found in plant host tissue.  Three P. occidentalis 
extracts analyzed were analyzed: healthy leaf tissue, leaf tissue from a plant host infected with 
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Xylella fastidiosa, and wood tissue from a healthy specimen.  Each tissue sample was extracted 
successively with hexanes, chloroform, and methanol.   
Table 5 Extracts of P. occidentalis tissue 
 Hexanes 
ext.(mg) 
Chloroform ext. 
(mg) 
Methanol ext.(mg) 
Symptomatic leaf (1.06 g) 7.3 6.1 3.8 
Asymptomatic leaf (0.892 g) 6.4 5.5 4.5 
Asymptomatic stem tissue (1 g) 2.4 1.9 9.6 
 
	  
Figure 34 Overlay of two extracted ion chromatograms of P. occidentalis extract and 
endophytic extract.  The m/z 1079.6 signal matches with previously purified iturin A3. 
 
 
The total weights for these extracts are collated in Table 5.  These extracts were analyzed 
using LC-MS.  The MeOH extract shared the same signal at m/z 1079.6 and the same retention 
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time (Figure 34).  This was the same signal that had previously been purified and solved by 
NMR and HRMS as iturin A3. 
 
	  
Figure 35 Extraction of P. occidentalis wood material	  
 
	  
Figure 36 Two EICs of putative rapamycin analog and rapamycin.  Top panel shows EIC of m/z 
913.7 from chloroform extract from P. occidentalis and middle panel shows EIC of sodium 
adduct of rapamycin at m/z 936.6 [M+Na]+.  Bottom panel shows signal for protonated signal at 
m/z 913.7, sodium adduct at m/z 935.7  and potassium adduct at m/z 951.7 for unknown. 
In order to complete a set of challenge experiments using MALDI-IMS, P. occidentalis 
wood material was ground to a fine sawdust material and extracted successively with hexanes, 
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chloroform, and methanol (Figure 35).  Although no rapamycin adduct signals were found in 
any of the P. occidentalis wood extracts, another signal was found in the chloroform extract 
which was very close in mass to the rapamycin signal (Figure 36).    In order to establish if this 
was a rapamycin analogue, the chloroform extract was further purified following the procedure 
outlined in Figure 37.  After purification, 5 mg of the purified extract was further resolved by 
HPLC monitoring the UV absorption maximum for rapamycin at 278 nm (Figure 38).    
 
	  
Figure 37 Isolation of putative rapamycin analogue 
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Figure 38 Putative rapamycin analogue purification.	  	  UV wavelength is 278 nm. 
 
	  
Figure 39 HRMS of putative rapamycin analog. 
Fractions were analyzed after HPLC by direct injection and the indicated signal contained the 
putative rapamycin analogue.  HRMS for this signal was gathered and this fraction was 
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submitted for FTMS (Figure 39).    
As was seen in earlier parts of this thesis and is documented in numerous publications, 
achieving reliable microbial production of secondary metabolites can be problematic.  One of the 
strategies for trying to help solve this problem is to try and develop an understanding of how the 
plant host regulates secondary metabolite production from the endophyte.  A series of 
experiments was designed using MALDI-IMS to test if extracts of P. occidentalis would up-
regulate iturin metabolites that had been characterized from the Bacillus sp.  There was a 
significant risk that the solvent used for extraction (either hexanes, chloroform, methanol) would 
cause problems in bacterial growth and lead to differences in secondary metabolite production 
that could be interpreted as the P. occidentalis host regulating the Bacillus sp. endophyte as a 
false positive.  Therefore, the first experiment was a time course experiment that involved plating 
a 5 µL B. amyloliquefaciens glycerol stock onto a series of seven different CS20 plates and 
surrounding these newly plated colonies with 10 µL of each solvent at approximately the same 
distance from different sides of the colony.  These plates were incubated at 36 °C and monitored 
for growth.  After four days bacteria had grown over all three solvents.  The bacterial margin did 
not show any variability depending on whether or not it expanded over the areas where solvents 
had been placed and iturin production was uniform throughout the colony area (Figure 40).  The 
next step was to test the extracts to see that, when the endophyte colony came into contact with 
one or more of the host plant extracts, iturin production increased. This was done by designing a 
time course experiment which involved plating 5 µL of glycerol stock of the endophyte in the 
center of 5 different CS20 solid agar plates.  These were then surrounded by the three different 
P. occidentalis extracts on three different sides of the colony.  Extracts were generated by 
successively extracting host wood material with hexanes, chloroform, and methanol (Figure 41).  
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These extracts were re-dissolved in the original solvent using a pre-calculated volume so that 10 
µL of liquid extract would equal half  a milligram of extract.  These were placed in such a way 
so that, over the five day period, the bacterial colony would expand to eventually come in contact 
with the extracts.  It was important to have the extracts placed sufficiently far away to allow for 
imaging the colony before it reached the extracts but also not too far away as to prevent the 
colony reaching the extracts in 5 days.  On day one the colony is expanding but has not yet 
reached the edge of any of the extracts and the intensity of iturin production is fairly uniform 
throughout the colony and outside the colony (Figures 42 & 43).  On day three there the colony 
has come closer to all extracts and there seems to be a slight increase in iturin intensity as a solid 
band as it is coming into contact with the chloroform extract (Figures 44 & 45).  
 
	  
Figure 40 MALDI-IMS iturin blank run.	  	  Bacillus sp. were analyzed by MALDI-IMS to 
ascertain if solvents affected either iturin production or Bacillus growth.  Iturin signal is shown 
as green. (H) hexanes, (C) chloroform, (M) is methanol.  (PB) is agar piece that bacterial colony 
was extracted from.  (B) is a separate agar plate of same media composition.  
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Figure 41 Extraction of P. occidentalis for MALDI-IMS challenge experiment 
 
	  
Figure 42 Bacillus sp. colony surrounded by host P. occidentalis extracts.(H) is hexane 
extract,(C) is chloroform extract, (M) is methanol extract.  Colony and extracts were excised 
after one day.  (PB) is agar piece that bacterial colony was extracted from.  (B) is a separate agar 
plate of same media composition. 
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Figure 43 Day one iturin production.	  	  Iturin intensity is relatively uniform throughout with the 
exception that more signals are found excreted from the colony.  Hexanes and chloroform 
extracts possibly inhibit iturin production.  (PB) is agar piece that bacterial colony was extracted 
from.  (B) is a separate agar plate of same media composition. 
 
 
	  
Figure 44 Bacillus sp. colony surrounded by host P. occidentalis extracts.  (H) is hexane extract, 
(C) is chloroform extract, (M) is methanol extract.  Colony and extracts were excised after three 
days. 
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Figure 45 Day three iturin production.  There is slight increase in iturin intensity as the Bacillus 
colony comes into contact with the chloroform extract. 
 
A clear increase in iturin production can be seen on day four after the Bacillus extract has 
come into contact with the chloroform extract (Figure 46).  This is seen clearly by representing 
the data in a different fashion using a heat map-like representation.  The inset shows which 
colors represent higher intensities with blue being the lowest intensity and red being the highest.  
All throughout the colony the intensity of the signals is mostly uniformly blue with higher 
intensities interspersed throughout the colony.  However, as the Bacillus colony comes into 
contact with the chloroform extract, the signals are clearly much more intense with more areas of 
green and there is red interspersed within green (Figure 46).  These results suggest something 
within the host chloroform extract is eliciting iturin production from B. amyloliquefaciens.   
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Figure 46 Day four iturin production.  The left panel shows the B. amyloliquefaciens colony 
coming into contact with the chloroform extract.  The middle panel shows there is a substantial 
increase in iturin intensity as the Bacillus colony comes into contact with the chloroform extract.  
This is highlighted by using a heat-map representation in the right panel.  The inset shows how 
color relates to intensity. 
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CHAPTER THREE: 
PURIFICATION OF NICOTIANAMINE FROM SOY FLOUR 	  
	  
Figure 47 Nicotianamine structure 
 
 Nicotianamine is a chelator of metals found in plants that has the ability to replace EDTA 
in food products to prevent spoilage.62 Because nicotianamine is ubiquitous among plant species, 
options for finding a viable source are broad. After searching for nicotianamine production and 
yields, soybeans and soybean products were chosen for the initial attempt to isolate significant 
amounts. The samples that were retrieved for analysis included whole commercially produced 
soybeans from five different hybrid species of whole soybeans and soy flour.  
 Whole soybean analysis.  The commercially available Asgrow 4531 strain soybeans 
(1.785 kg) from Monsanto-Asgrow brand markets in Leland, MS, were ground and soaked in  8 
L warm water (40 °C) for roughly 20 hours, and subjected to sonication. The aqueous extract (6 
L) was removed from the soybean material by use of mesh wiring filtration. Using a 1 M HCl 
solution, the pH of the resulting aqueous extract was adjusted to 4.5 to precipitate proteins. Using 
centrifugation, the proteins from the pellet were removed from the aqueous extract.  A total of 
5.5 L of supernatant was recovered and subsequently concentrated to 2.25 L using rotary 
evaporation.  2.25 L of ethanol was added to the concentrated aqueous extract in order to 
precipitate the nicotianamine-containing material. The mixture was stirred and placed under
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refrigeration overnight to maximize precipitation. The resulting mixture was centrifuged to 
separate the precipitate from the aqueous extract. The precipitate was lyophilized and yielded 15 
g of dry material.  
 Soy flour analysis. Soy flour was obtained from a 1.5 lb (680 g) bag of Hodgson Mill 
soy flour exp. date 11/10/12, barcode: 0 71518 05039 9.  To two 2800 mL flasks were added 200 
g of the flour. Water (2500 mL) was added to each and the pH was adjusted to 9 using sodium 
hydroxide and set to stir at 25 °C.  The suspension was filtered using wire mesh filtration and the 
pH was adjusted to 4.5.  The aqueous extract was centrifuged and the protein-containing pellet 
was removed.  Ethanol was added to the supernatant at a concentration of 80%.  The resulting 
solution was centrifuged and the nicotianamine-containing pellet was removed. The material was 
lyophilized to yield 12.4 g of dry material and nicotianamine was detected by LC-MS and 
compared to material generated from whole soybeans. 
  
Table 6 Calibration of NA using LC-MS 
      Nicotianamine (ng)                            Area                     Average area                      RSD 
210 1350 1224 9.34 
  1195 
  
 
1127 
  420 3579 3679 6.03 
 
3933 
  
 
3524 
  1050 9600 10248 5.47 
 
10565 
  
 
10578 
  2100 22021 22486 6.63 
 
24154 
  
 
21284 
  4200 39385 41203 5.59 
 
40431 
  
 
43794 
  *RSD (%)=((std dev*100)/mean) 
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Figure 48 Calibration curve for nicotianamine 
The first step in being able to quantify the yield of nicotianamine using LC-MS was to 
create a calibration curve using a nicotianamine standard.  Five different concentrations were 
used and each concentration was run three times (Table 6).  The average of three runs for each 
concentration were used to create a calibration curve which could be used to compare all future 
extracts for highest yielding methods (Figure 48).  Another important piece of data to generate 
was the detection limits of the LC-MS as well as the HRMS.  The detection limits were found to 
be approximately 4.2 ng (Figure 49) and the HRMS showed an [M+H]+ ion at m/z 304.1431. 
(Figure 50).   
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Figure 49 Detection limits of nicotianamine.	  	  4.2 ng was the lowest amount that could be 
detected. 
 
	  
Figure 50 HRMS of nicotianamine. 
After this data had been gathered, the yield from the two different sources could be 
quantified.  A comparison of the yield between whole soybeans and soy flour, which had been 
defatted, proved that soy flour was the optimal soy resource.  The ionization intensity of the 
extracted  [M+H]+ ion at  
m/z 304.1431 for nicotianamine is shown for the whole soy precipitate, soy flour precipitate and 
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the nicotianamine standard (Figure 51).  The integration intensity of extracted ion m/z  304.1431 
m/z for 20 µg soy flour precipitate, 20 µg whole soy precipitate, and 50 ng of pure nicotianamine 
standard was 621051, 228178, and 603387, respectively. The following equations give the 
percent composition of nicotianamine in the precipitate mixtures: 
A.  [(50 ng pure NA * 621051) / (603387)] / (20000 ng crude precipitate) * 100% = 
0.26% NA in soy flour precipitate. 
B.  [(50 ng pure NA * 228178) / (603387)] / (20000 ng crude precipitate) * 100% = 0.1% 
NA in whole soy precipitate.   
Based on this analysis, it was decided that soy flour was the best viable option to attempt 
to purify nicotianamine.  The Kikkoman corporation describes a patented method for the  
	  
Figure 51 Comparision of nicotianamine from whole soybean precipitate, soy flour precipitate, 
and nicotianamine standard. 
extraction of nicotianamine from soy flour which was followed, with some steps adjusted as 
needed (Figure 52).64 
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Eighty grams of Hodgson’s Mill soy flour was used. The first step involved adding one 
liter of water to this dry material and adjusting the pH to 9 using 6 M NaOH.  A stir plate was 
used and this mixture was stirred for approximately two hours.  This material was then filtered 
through a stainless steel sieve.  The pH was then adjusted to 4.5 and the material was centrifuged 
at 4000 RPM for 30 minutes in order to precipitate the proteins from the solution.   
Thirty grams of activated carbon was then added to this solution and it was stirred using a 
magnetic plate and stir bar for approximately four hours.  Afterward, filter aid was added and the 
solution was stirred for approximately one more hour.  This material was then filtered and 
lyophilized yielding approximately 17 grams.  LC-MS quantification showed a yield of 
approximately 0.3% nicotianamine (Figure 53).   
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Figure 52 Nicotianamine isolation scheme 
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Figure 53 Yield of nicotianamine from soy flour 
	  
Figure 54 Yield of nicotianamine from soy flour after multiple purification steps 
This freeze dried material was dissolved in 50 mL of H2O.  Next, this solution is made 
into an 80% solution of ethanol on a w/w basis by adding 130 mL of ethanol.  This mixture was 
then centrifuged for 30 minutes at 4 °C at 4000 RPM.  The supernatant was discarded and the 
pellet is kept.  After lyophilization, this material contained 1.0% nicotianamine (Figure 54). 
 In order to test this material and be sure that nicotianamine was the ion signal that 
was being analyzed, a co-injection with the nicotianamine standard was performed (Figure 55).  
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Figure 55 Co-injection of nicotianamine and extract 
 This scheme provides a relatively straight-forward way to purify a natural metal-
chelating agent from a cheap, readily available source.  Nicotianamine could replace EDTA to 
prevent metal-catalyzed spoilage and still enable food products to be labeled as “all-natural.”  
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   CHAPTER FOUR: 
                                                                   HCV REVIEW 
 
The goal of HCV therapy is a sustained virologic response (SVR), which is achieved 
when HCV RNA cannot be detected in serum 24 weeks after therapy has ended.  The currently 
prescribed therapy against HCV is a combination of ribavirin and either peginterferon alfa-2a or 
peginterferon alfa-2b.    Less than half of patients infected with HCV genotype 1, the most 
prevalent genotype in patients in the United States, achieve an SVR with standard 
ribavirin/interferon combination therapy.94 The FDA recently approved two protease inhibitors, 
telaprevir and boceprevir, for the treatment of genotype 1 HCV. Telaprevir has been shown to 
significantly improve the SVR in patients when administered along with the HCV standard 
combination therapy of ribavirin and peginterferon.95 However, the chance that patients will 
discontinue therapy due to adverse side effects is also increased.95 There have been significant 
differences in response to therapy based on genotype.  For example, in one recent clinical study 
patients infected with genotype 1 showed a decrease in viral load of 4.4 log10 IU/mL after two 
weeks of monotherapy of telaprevir; patients with genotype 4 HCV only showed a decrease of 
0.9 log10 IU/mL.96 Differences in efficacy have also been noted in NS5B non-nucleoside 
inhibitors as well.  In another recent clinical study, VCH-259, a DAA that binds to the thumb 2 
site of the NS5B RdRp, was administered for 10 days to an HCV genotype 1 patient after which 
HCV RNA had decreased by a mean maximal of 2.5 log10 IU/mL.  The same conditions were 
tested for a patient infected with genotype 6 and no viral decline was reported.97  
The two most recent drugs approved for HCV treatment are simeprevir (Olysio®) and
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sofosbuvir (Solvaldi®).98-99 Simeprevir is an NS3/4 protease inhibitor  that has been shown to 
significantly increase SVR rates in patients with genotype 1 after 24 weeks when given in 
combination with interferon and ribavirin when compared to interferon and ribavirin alone or 
placebo.100 Sofosbuvir is a RNA polymerase inhibitor that has been shown to significantly 
increase SVR rates in both genotype 1 and 4 patients when given with ribavirin and interferon.101 
Interestingly, sofosbuvir has also shown efficacy in genotype 1 patients in combination with 
ribavirin but without interferon.102  This represents a major step forward as interferon side effects 
often stop patients from continuing a full regiment of HCV.  However, the cost of these new 
drugs can be a major issue for certain segments of the population, especially for people in 
developing countries.  The giant steps forward in knowledge of the HCV life cycle played a huge 
role in     the development of these new agents and have also allowed for screening of natural 
product leads for HCV. 
HCV is an enveloped virus containing a lipid bilayer that surrounds the nucleocapsid.  E1 
and E2 are two structural glycoproteins that are anchored in the lipid bilayer and participate in 
host cell receptor binding. Recent studies have shown that E1 and E2 are stabilized by covalent 
disulfide bridges once exported to the bilayer and that glycosylation of certain sites are vital for 
both infectivity and evading the host immune response.103 There have been numerous studies 
attempting to elucidate the mechanism for HCV binding.  The low-density lipoprotein receptor 
(LDL-R),104 the cell receptor CD81,105 the human scavenger receptor class B type I (Sr-BI),106 
and claudin-1,107 a protein involved in tight-junction cell-to-cell adhesion, have all been studied 
to understand their roles in HCV entry. 
 The HCV genome is composed of a ~9600 bp length, positive sense strand mRNA that is 
translated by a negative strand intermediate.  The genome includes: a 5´ non-coding region 
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(NCR) that contains the internal ribosome entry site (IRES), the ORF that encodes the single 
polyprotein, and the 3´ NCR.108 The IRES directs translation of HCV mRNA by a mechanism 
that is distinct from host cell eukaryotic translation.109 The HCV ORF encodes, starting from the 
5´ end: the core nucleocapsid; the E1 and E2 envelope proteins; the p7 ion channel; the NS2-3 
protease; the NS3 serine protease and RNA helicase; the NS4A polypeptide; the NS4B and 
NS5A proteins; and the NS5B RNA-dependent RNA polymerase (RdRp).110 The developing 
polyprotein is processed by both the host endoplasmic reticulum signal peptidase and the NS2-3 
protease and the NS3-4A serine protease.110 The polyprotein product contains a signal sequence 
between the core nucleocapsid encoding region and the E1 envelope coding region which directs 
it to the host endoplasmic reticulum (ER) membrane.111  After the E1 region has been 
translocated into the endoplasmic reticulum, the core protein is cleaved and processed and 
subsequently associates with lipid droplets.111 The E1 and E2 proteins are glycosylated by the 
host ER and ER chaperones are involved in proper E1 and E2 folding.112 
 The p7 ion channel has been shown to be vital for infectivity using mutational studies, 
and also for viron assembly by interacting with the NS2 and E1 proteins.113 Another possible role 
for this protein may be to regulate pH in intracellular compartments of the host cell.114 
 HCV relies on two proteases; the first, NS2-3, is responsible for a single cleavage at the 
NS2/NS3 junction.  The next protease, the NS3-4A serine protease and RNA helicase complex, 
is responsible for cleavage between the NS3/4A cofactor (self-cleavage), and between the 
NS4A/4B, NS4B/5A, and NS5A/5B proteins.73,115  
 The NS4B protein is involved in forming the membranous network where HCV 
replication takes place,116 while the NS5A proteins has proven to contain RNA binding 
properties,117 be involved in alpha-interferon resistance,118 and possibly contribute to liver 
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steatosis.119 The final protein in the ORF sequence is the NS5B RNA-dependent RNA 
polymerase (RdRp), which is responsible for synthesizing a negative-strand template from the 
original positive oriented strand to facilitate positive strand replication, and is used in HCV 
classification. 
 Less is known about HCV packaging and assembly, but there has been a number of 
studies published in this area in recent years.120 One study has suggested that HCV co-opts the 
cellular production and release of very-low-density-lipoproteins (VLDL), which, through a kind 
of mimicry, allows HCV to persist.121 One particular protein involved in VLDL production that 
seems to be important in HCV production is apolipoprotein E.122  Other proteins that have been 
implicated in HCV production are heat shock cognate protein 70,123 annexin A2,124 and 
diacylglycerol acyltransferase-1.125 
Plant Derived HCV Natural Product Inhibitors  
 The HCV NS3-4A protease as emerged has a primary target for DAA agents. Four new 
iridoid glucosides were recently isolated from Anarrhinum orientale, a plant in the order 
Lamiales.  Iridoids are monoterpene glycosides which are widely found in Lamiales.126  One of 
these newly isolated irdoids (1), had an IC50 value of 100 µM against the NS3 protease (Figure 
42).  This compound also showed selectivity for the HCV NS3-4A protease as the IC50 values for 
the human trypsine protease were above 200 µM.126 
A recent study that screened more than 150 plants with reported medicinal properties for 
anti-HCV activity showed activity in the methanol extract of the root bark of species in the 
Morus genus.127 Bioassay-guided fractionation yielded five known 2-arylbenzofuran derivatives 
from the original extract. Four of these compounds mulberroside C, moracin P, moracin O, and 
moracin M, showed inhibitory activity against HCV, with moracin P and moracin O showing 
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potent activity.  Moracin P (2) had an IC50 value of 35.6 µM and moracin O (3) an  IC50 of 80.8 
µM in a Huh-7 cell replicon assay. These compounds were further tested for specific activity 
against NS3-4A helicase activity.  Moracin O had an IC50 of 42.9 µM, while moracin P showed 
an IC50 of 27.0 µM.127 
	  
Figure 56 Plant-derived inhibitors of HCV 
Another recent study screened a natural product compound library derived from 
American and African flora for anti-HVC activity and found HCV inhibition in extracts of the 
aerial parts of Parthenium hispitum.128 Bioassay guided fractionation yielded a series of 
pseudoguaianolides, a group of sesquiterpene lactones, three of which (4-6) yielded primary 
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inhibition of HCV above 90% at a 2 µM concentration.128 Shikonin (7) is a naphthoquinone 
derivative that has been isolated from Arnebia euchroma in past studies and shown activity 
against HIV-1 in vitro and has antiangiogenic and antitumorigenic properties.129 It was recently 
tested against HCV and had an EC50 value of 0.025 µg/mL.130 Further cytotoxicity test proved 
the selectivity index of shikonin to be relatively high at 43.56 (CC50/EC50).130 
Diosgenin (8) is a steroidal sapogenin that has been isolated from tubers in the genus 
Dioscorea.  A recent study that tested diosgenin against HCV using an enhanced green 
fluorescent protein reporter based assay demonstrated an EC50 value of  3.8 µM.131 Further 
experiments using Western blot analysis showed that diosgenin had an additive effect when 
administered with interferon-alpha on inhibition of the HCV NS3-4A protease.131 
Another large scale screening procedure which utilized plants used in traditional 
medicine in Sudan yielded two benzoquinones that showed significant activity against the HCV 
protease.132 These two compounds, embelin (9) and 5-O-methylembelin (10) were isolated from 
the fruit of an Embelia schimperi species.  Embelin gave an IC50 of 21 µM, while 5-O-
methylembelin gave a reported IC50 of 46 µM when tested for inhibitory activity against the 
HCV NS3-4A protease.132 
Another study, this time involving screening plants from Peru, yielded two new 
polyphenolic compounds that showed significant activity against the HCV NS3-4A protease.133 
Both compounds were isolated from the methanol extract of Stylogone cauliflora.  SCH 644342 
(11) showed an IC50 value of 0.8 µM, while SCH 644343 (12) gave an IC50 value of 0.3 µM.133 
Microbial Derived HCV Inhibitors 
In 1996, a new quinone compound, SCH 68631 (13), was isolated from the fermentation 
broth of a soil microorganism isolated from a forested area in Nepal (Figure 43).134 The original 
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material was extracted with ethyl acetate and a biphasic solvent partitioning system was used for 
further purification.  The active fraction was then subjected to HPLC.  SCH 68631 gave an IC 
value of 2.5 µg/mL when tested against the NS3-4A protease.134 
Another novel compound from a soil microorganism was isolated in 1999 that showed 
high anti-HCV activity. Penicillium griseofulvum is a fungus that was isolated from a desert 
ecosystem in Arizona.135 The fermentation broth of this organism was extracted with ethyl 
acetate and then purified using liquid partitioning and HPLC, yielding SCH 351633 (14), a novel 
bicyclic hemiketal lactone.  This new compound gave an IC50 value of 3.8 µg/mL when tested 
against the HCV NS3-4A protease.135 
Marine Derived HCV Natural Products Inhibitors 
Manoalide (15) is sesterpenoid first isolated from the sponge Luffariella variabilis.136 It 
was recently screened for antiviral activity and was shown to inhibit the ATPase, RNA binding, 
and helicase activities of the HCV NS3 protease.136 
	  
Figure 57 Microbial-derived HCV inhibitors 
  The discorhabdins are a group of pyrroloiminoquinone alkaloids derived from sponge 
species in the genus Latrunculia.  Two compounds in this class have shown potent activity in an 
HCV replicon assay.137 Discorhabdin A (16) had an EC50 value above 90% at concentrations less 
than 10 µM.137 
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Figure 58 Marine-derived inhibitors of HCV 
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CHAPTER FIVE: 
                                                                CONCLUSIONS 
 
 Platanus occidentalis and Bacillus amyloliquefaciens 
Endophytes are bacterial and fungal symbionts that reside in plant tissue without causing 
disease and numerous studies have proven these microbes are engaged in a symbiotic 
relationship with the host plant.  The functions that the endophytes provide for the host are 
varied and studies on the ecology of endophytes are still ongoing, but the nature of these 
relationships has been elucidated in many host plant species and is of great importance to many 
important agricultural crops.  For example,  endophytes that reside in the leaves of Theobroma 
cacao enhance host defenses against the pathogen Phytophthora palmivora.138 In rice (Oryzae 
sativa), endopytes regulate resources to optimize root growth while root hairs are being 
established.139 Another recent study showed that in wheat (Triticum spp.), endophytes help host 
plants to adapt to heat and drought conditions.140 
 Bacillus spp. of bacteria are known to produce a diverse set of secondary metabolites 
including lantibiotics, lipopeptides, polyketides, and others.17 Rapamycin is a polyketide 
molecule which is of major interest due to wide-ranging activity including antitumor42 and 
immunosuppressant activities43 and research into the efficacy of  rapamycin against many human 
ailments is ongoing.  Here we have increased the knowledge base in regards to this important 
molecule in a number of ways.  We have shown that another species other than Streptomyces 
hygroscopicus produces this important molecule.  The fact that a Bacillus species produces 
rapamycin could have wide ranging effects in the pharmaceutical industry as Bacillus species are 
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historically very amenable to genetic engineering.  Typically, drug molecules that are produced 
by microbial species have been modified and engineered to increase production of the molecule 
of interest.  Actinomycetes are known to be much more difficult to grow than Bacillus spp. and 
thus this strain of B. amyloliquefaciens could be a viable alternative to develop.  Genetic 
engineering methods for increasing production would need to be developed in order to compete 
with current rapamycin producers.    
Another finding that is important to rapamycin research is the possible discovery of a 
rapamycin analogue.  One of the many reasons the original report of rapamycin was such an 
important discovery was not in regards to the molecule itself, but was due to the fact that this led 
to the discovery of Target of Rapamycin (TOR) protein kinases.44 TOR is important in both 
primary and clinical biology; in primary biology, it is the main controller of cellular growth and 
aging in eukaryotic cells that coordinates environmental signals with the appropriate response.141 
As mentioned previously, TOR proteins are part of at least two protein complexes, TORC 
(Target of Rapamycin Complex) 1 and TORC2.  Interestingly, rapamycin only binds to TOR that 
is part of TORC1 and thus analogues would be of high interest to test binding differences in 
these different complexes.  TORC1 signaling is thought to be overactive in a majority of cancers, 
so any differences in binding or subsequent activity in TOR as part of TORC1 would be of 
substantial interest as well.45 Although there have been substantial leaps in knowledge with 
regards to TORC1 and TORC2 signaling and activation, this is still an active area of research.45 
If the putative rapamycin analogue binds to either complex in a distinct manner, this could assist 
biochemical investigations of these pathways.  
Another way that this work has contributed to the study of secondary metabolites is by 
demonstrating the need for future investigations into silent gene expression from microbial 
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species.  Natural products are responsible for greater than 70% of antibiotics and 55% of 
antiviral medications.142 Most of these were discovered in the 1940s and 1950s in what is now 
heralded as the Golden Age of Antibiotics.143 A number of  strategies have been developed in 
order to try and elicit or activate silent gene clusters that are not active under normal laboratory 
conditions.143 Here, we show a Bacillus species from the very common P. occidentalis has the 
ability to produce rapamycin, a secondary metabolite that was first discovered on Easter Island, 
2000 miles of the coast of Chile.  This shows how a deeper understanding of silent gene 
expression, and also the chemical ecology underlying the endophyte-host plant relationship, will 
be important for future drug discovery efforts. 
Perhaps the most intriguing part of this work was the possible biotransformation of the 
rapamycin metabolite by the host plant.  Rapamycin has been shown to be detrimental to plant 
growth, yet also contains strong antifungal activity that the host plant could utilize to ward off 
pests.  It will be of great interest to determine if the putative analogue is also detrimental to plant 
growth and how overall binding to rapamycin sensitive proteins is affected by structure changes.  
Certain Bacillus spp. are known to be plant growth promoters.144  Owing to the wide ranging 
effects of rapamycin on TOR there are many different hypotheses that could be developed to 
explain rapamycin production by Bacillus spp. and the subsequent putative biotransformation 
product.  
The MALDI-IMS challenge experiment demonstrates an important, innovative way to try 
and understand plant-endophyte relationships and host regulation of endophyte-produced 
secondary metabolites.  B. thuringiensis (Bt) has been used in the past in agriculture and other 
applications due to its ability to produce insecticidal proteins.15 Efforts have been underway to 
improve production of these proteins and to increase the ability of Bt to act as a biopesticide 
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using genetic manipulation.145 As mentioned previously, Bacillus spp. produce the antifungal 
lipopeptide iturins and these molecules have proven activity against a number of agricultural 
pathogens including those associated with powdery mildew and root rot.29  There is a proven link 
between the level of iturin production from endophytic Bacillus spp. and the ability of Triticum 
spp. to fight the fungal infection Fusarium head blight.146 An understanding of how the plant 
hosts regulate the production of this lipopeptide could be an important component in developing 
methods to increase the output of iturin production in the field.  Understanding host regulation of 
endophyte-produced natural products is also an important facet of natural product drug research.  
Nicotianamine 
There has been a general trend in the market place towards all-natural or organic foods.65 
Food industries that attempt to provide products which are packaged as “all-natural” can 
encounter significant problems when attempting to prevent long term food spoilage.  
Ethylenediaminetetraacetic acid (EDTA) is a common metal chelator that is added to food 
products to prevent spoilage.  As a synthetic product, addition of this agent disables food 
companies of the ability to label their products as all-natural or organic, even if strict protocols to 
growing all natural or organic foods have been followed.   
Nicotianamine is a natural metal chelating agent which presents a viable alternative to 
EDTA in the food industry.  Here, we show that nicotianamine can be obtained from readily 
available soy flour.  This soy flour was easier to manage and contained a higher yield of 
nicotianamine when compared to a trial that used whole soybeans.  In addition, although 
patented methods contained a variety of methods for nicotianamine purification, here we report 
that ethanol precipitation after activated carbon treatment was a vastly improved strategy due to 
lowering the amount of ethanol needed for precipitation.  This is particularly important to food 
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conglomerates which might produce soy products in certain areas of their overall business plan 
and could use resources that are already available to produce a natural replacement for EDTA.  
The Hepatitis C Virus 
The hepatitis C virus (HCV) is responsible for chronic hepatitis C, which can lead to 
cirrhosis of the liver and hepatocellular carcinoma.  This is a major health concern as an 
estimated 130-170 million people worldwide are infected with HCV.68 More than 350,000 
people die from chronic HCV related diseases annually every year, with an estimated 3-4 million 
new individuals infected each year.68  Co-infection with HIV is also a major concern as this 
increases the chances of liver disease three fold.69 
Here, we review natural products that have shown in vitro HCV activity.  The latest 
findings on HCV proteins and the HCV life cycle are reviewed as well.  The discovery of the 
HCV virus and the elucidation of its life cycle has happened in relatively recent times.  
Difficulties in culturing this virus was the major hurdle in discovering the etiologic agent of 
hepatitis C.  These difficulties have largely been overcome and permitted novel screening 
techniques of natural products against different targets of HCV.  As demonstrated in this review, 
natural products are an important source of active metabolites against new targets for HCV
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EXPERIMENTAL SECTION 
 
Glycerol Stocks: There were a total of six glycerol stocks supplied by Dr. Mohammed 
Ibrahim.  Glycerol stock labeled Xf1 was used to make multiple other glycerol stocks by plating 
5 µL of Xf1 glycerol stock on solid agar and allowing it to grow at 36 °C for 48 hours.  Colonies 
were then streaked using sterile technique into 10:5 milliliters of liquid CS20 media. Tubes were 
shaken for approximately 48 hours at 36 °C at 160 RPM in a New Brunswick Series 25 
Incubator Shaker.  These cultures were used for creating a total of 30 glycerol stocks by 
removing 600 µL of media and adding to Eppendorf tubes and mixing with 400 µL of 60% 
glycerol stock solution.  Glycerol stocks were placed in Thermo Fisher Scientific -86 °C freezer. 
Endophyte isolation: P. occidentalis stem material was surface sterilized using 80% 
EtOH for 4 minutes under bio-hood under sterile conditions.  Bio-hood was UV irradiated prior 
to endophyte isolation.   Outer bark was peeled off using knife and forceps that had been soaked 
in 80% EtOH for ten minutes and flamed.  Inner layer of bark tissue and exposed inner stem 
were placed directly on malt agar.  Agar plates were sealed with Parafilm® in bio-hood.  Plates 
were incubated at 36 °C for 48 hours.  Bacterial growth emerged directly from exposed stem 
material.  Bacterial colonies growing directly from exposed stem were sub-cultured under sterile 
conditions.  Sub-cultured plates were used to make (10) 5 mL liquid cultures using sterile 
conditions.  5 mL liquid cultures were shaken at 160 RPM and 36 °C for 24 hours.  Glycerol 
stocks were made by pipetting 600 µL of liquid culture and 400 µL of 80% glycerol into 
Eppendorf tubes.  Tubes were placed in -80 °C freezer for storage.
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HP-20 extractions:  The first step in testing secondary metabolite production was to 
plate 5 µL of glycerol stock on solid agar CS20 plates.  After 48 hours of growth at 36 °C, 
cultures were streaked from plates under sterile conditions into 2:5 mL tubes of liquid CS20 
media.  In the first extraction process, 2:100mL cultures were inoculated using the 5 mL starter 
cultures. Cultures were removed and sonicated in a Branson 8510 Ultrasonic Cleaner for one 
hour.  Afterwards, cultures were centrifuged in an ThermoIEC Centra CL3R centrifuge for 10 
minutes at 4000 RPM.  The cell pellet was subsequently discarded.  HP-20 Diaion resin beads 
(10 g) were added to each of the 100 mL flasks and flasks were put back in the shaker for 12 
hours.  HP-20 beads were filtered using a Buchner funnel and Whatman No. 1 filter paper.  The 
liquid was subsequently discarded and 100 mL of EtOH was passed over beads followed by 100 
mL of EtOAc.  Note that for all subsequent extractions the amount of liquid used for each 
solvent was equal to the original amount of culture that was fermented.  Each extract was 
evaporated in a Büchi R-200 Rotavapor in conjunction with a Büchi B-490 heating bath.  In 
order to complete evaporation, samples were placed in a Savant Speed-Vac SC210A in 
conjunction with an FTS 8L vapor trap. 
NPNCR Bioassays: The general procedure was as follows.  Crude extracts were tested in 
a primary screen which used a concentration of 50 µg/mL and tests extracts in duplicate.  Percent 
inhibitions were calculated relative to positive and negative controls.  A total of 5 pathogenic 
bacteria and 5 pathogenic fungi were used for screening.  These include: C. albicans, C. 
glabrata, C. krusei, A. fumigatus, and C. neoformans in the fungal category, and: Staph. aureus, 
MRSA, E. coli, P. aeruginosa, and M. intracellulare in the bacterial category. The amount of 
crude material that was submitted was in the range of 10-90 mg of material.  This work was 
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completed under a grant by NIH, NIAID, Division of AIDS, grant number: AI 27094.  
Screenings were performed by Ms. Marsha A. Wright and reported by Dr. Melissa Jacob.     
LC-MS. Samples were prepared by dissolving 1 mg of material into 1 mL of MeOH.  
Samples were run using a 20 µL injection volume.  Method used ran a gradient of 80% H2O/20% 
MeOH to 100% MeOH over a period of 24 minutes.  Each solvent had 0.05% formic acid added 
prior to being used a with binary pump.  
Challenge Experiment P. occidentalis wood was processed into sawdust. Wood was 
lyophilized using a Labconco ® FreeZone 2.5 L Freeze Dry System. This material was then 
extracted with hexanes, chloroform, and methanol using a total of three extractions for each 
solvent.  The material was then covered with solvent and placed in a a Branson 8510 Ultrasonic 
Cleaner for one hour, filtered through a a Buchner funnel, and the solvent evaporated a Büchi 
rotary evaporator R-200 used in conjunction with a Büchi B-490 heating bath.  The same 
procedure was repeated a second time using the same solvent and the same material.  For the 
third extraction, the same procedure was followed, with the exception that after sonication the 
material was left in solvent overnight for approximately 24 hours before extraction using the 
Buchner funnel.  Following rotary evaporation, all extracts were placed in a Savant Speed-Vac 
SC210A in conjunction with an FTS 8L vapor trap to remove solvent.  The glycerol stock (5µL) 
was placed in the center of 5 different CS20 solid agar plates.  These were then surrounded by 
the three different P. occidentalis extracts on three different sides of the colony.  These extracts 
were re-dissolved in the original solvent with using a pre-calculated volume so that 10 µL of 
liquid extract would equal half  a milligram of extract.  These were placed in such a way so that 
over the 5 day period, the bacterial colony would expand to eventually come into contact with 
the extracts.  It was important to have the extracts placed sufficiently far away which would 
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allow for imaging the colony before it reached the extracts but also not too far away which 
would prevent the colony reaching the extracts in five days.  
Genome Assembly Bacillus sp. was sequenced by collaborators at University of 
Maryland and submitted as two fastq files (R1 and R2).  Geneious software was used for 
assembly.  Mapping assembly was used with NCBI reference sequence Bacillus subtilis 
NC_000964.3.  Sensitivity settings were set to medium.
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